Germany Taps AI for National Lung Cancer Screening at Top Berlin Hospital

BERLIN, Germany – March 23, 2026 – In a landmark move for Germany's public health strategy, Charité – Universitätsmedizin Berlin, the nation's largest and most prestigious university hospital, has integrated a sophisticated artificial intelligence solution to power its lung cancer screening efforts. The hospital has adopted AVIEW LCS Plus, a leading AI platform from medical technology firm Coreline Soft, positioning the technology at the heart of Germany’s impending national lung cancer screening (LCS) program.

This implementation is more than a simple technology upgrade; it represents a critical step in a nationwide shift from scattered pilot projects to a cohesive, standardized screening system. With Charité serving as a national benchmark for clinical guidelines, its choice of AI infrastructure is expected to set a powerful precedent for healthcare institutions across the country as they prepare for a new era in early cancer detection.

A National Shift to Standardized Screening

The timing of this partnership is pivotal. Germany is on the verge of a historic transformation in its approach to lung cancer, the leading cause of cancer-related death in the country. The Federal Joint Committee (G-BA), the highest decision-making body in Germany's public health system, has approved low-dose computed tomography (LDCT) screening as a statutory health insurance benefit. The national program, anticipated to launch by April 2026, will target a high-risk population of current and former heavy smokers between the ages of 50 and 75.

This transition moves Germany away from the fragmented, institution-by-institution adoption of screening tools. The new national framework demands a robust, interconnected infrastructure capable of managing a massive volume of data with unwavering consistency and quality. The G-BA has mandated strict quality assurance protocols, including a mandatory “double-reading” of any scan showing findings that require follow-up. This protocol, designed to minimize false positives and the patient anxiety they cause, creates a significant logistical challenge.

Industry experts note that the market is rapidly evolving from a competition based on individual product performance to one centered on comprehensive, infrastructure-level solutions. The new reality requires platforms that can manage multi-center operations, seamlessly integrate double-reading workflows, ensure data pseudonymization for patient privacy, and internalize quality control—all while reducing the immense workload on a limited pool of specialized radiologists. The successful HANSE project, a national LCS pilot program that helped inform the G-BA's decision, previously verified the operational stability of Coreline Soft's solution in such a multi-center environment.

Charité: The Ultimate Proving Ground for Medical AI

Charité's role in this initiative cannot be overstated. Consistently ranked as Germany's top hospital and 7th globally by Newsweek, the Berlin-based institution is a powerhouse of clinical practice, research, and policy influence. Its decisions on technology and clinical pathways often serve as the blueprint for national standards, making its adoption of AVIEW a powerful endorsement.

The hospital is no stranger to pioneering AI in medicine. Through dedicated initiatives like the Charité Lab for Artificial Intelligence in Medicine (CLAIM) and strategic partnerships with technology giants like Siemens Healthineers and Intel, Charité has actively worked to integrate machine learning into diagnostics, treatment planning, and clinical workflow optimization. This established commitment to digital innovation makes it the ideal environment to validate and refine an AI-driven screening infrastructure before its nationwide rollout.

By embedding Coreline Soft's AI into its workflow, Charité is not just enhancing its own diagnostic capabilities; it is creating a real-world model for how to execute a high-quality, efficient, and scalable national screening program. This provides a critical proof-of-concept for other hospitals and clinics that will soon be required to meet the G-BA's stringent standards.

Beyond Nodule Detection: An Integrated Health Assessment

The technology at the center of this initiative, AVIEW LCS Plus, goes far beyond simple nodule detection. The AI-powered solution automatically analyzes a single low-dose CT scan for three critical conditions: lung nodules, Chronic Obstructive Pulmonary Disease (COPD), and Coronary Artery Calcification (CAC). This integrated approach provides a more holistic view of a patient's thoracic health from a single, low-radiation imaging session, maximizing the diagnostic value of each screening.

To manage the complex logistics of the national program, the system is complemented by AVIEW HUB, a centralized management platform. This infrastructure layer is specifically designed to address the new market demands. It facilitates the double-reading protocol, manages interpretation histories for consistency, and internalizes quality control, effectively creating a command center for multi-site screening operations.

This combination of precise, multi-faceted analysis and robust operational management is what positions Coreline Soft to meet the evolving needs of national health systems. The company has already secured its role in major European screening projects in France (IMPULSION) and Italy (RISP), demonstrating the strength of its multi-center strategy.

Redefining Patient Care and Clinical Efficiency

For patients, the widespread implementation of this technology promises earlier and more accurate diagnoses. Lung cancer survival rates are dramatically higher when the disease is caught at its earliest stages. By helping radiologists detect subtle or small nodules that might be missed by the human eye, AI can significantly improve the chances of successful treatment. Furthermore, by reducing false-positive findings, the technology helps spare patients from the stress and risk of unnecessary follow-up procedures.

For clinicians, the benefits are centered on efficiency and confidence. AI automates time-consuming tasks like image segmentation and measurement, allowing radiologists to focus their expertise on complex analysis and final decision-making. In a national program that will generate hundreds of thousands of scans, this efficiency is not a luxury but a necessity. The AI acts as a tireless, consistent second reader, enhancing diagnostic accuracy and reducing inter-reader variability across the entire healthcare system.

As Germany prepares to launch its ambitious national screening program, the integration of advanced AI at a leading institution like Charité marks a defining moment. It signals a clear commitment to leveraging technology not just as a tool, but as the foundational infrastructure for a new standard of preventive public health.